ACADIA PHARMACEUTICALS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
ACADIA PHARMACEUTICALS INC. (ACAD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of -$4.11 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2025-02-27
- ACADIA PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-09-30 was $465.00K.
- ACADIA PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-06-30 was -$532.00K, a 176.88% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2024-03-31 was -$4.05M, a 2133.67% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2024 was -$4.11M, a 238.80% decline from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2023 was $2.96M.
- ACADIA PHARMACEUTICALS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2022 was -$1.39M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $465.00K derived: sum of 2 quarters · filed 2025-02-27 | -$67.00K derived: sum of 3 quarters · filed 2025-02-27 | -$4.11M 10-K · filed 2025-02-27 |
| 2024-09-30 | $465.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$67.00K derived: sum of 2 quarters · filed 2024-11-07 | -$4.11M 10-Q · filed 2024-11-07 | -$975.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | -$532.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$4.58M 10-Q · filed 2024-08-07 | -$1.44M derived: sum of 3 quarters · filed 2024-08-07 | -$2.51M derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | -$4.05M 10-Q · filed 2024-05-09 | -$908.00K derived: sum of 2 quarters · filed 2024-05-09 | -$1.97M derived: sum of 3 quarters · filed 2024-05-09 | -$1.28M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.07M derived: sum of 2 quarters · filed 2024-02-28 | $2.77M derived: sum of 3 quarters · filed 2024-02-28 | $2.96M 10-K · filed 2024-02-28 |
| 2023-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$374.00K derived: sum of 2 quarters · filed 2023-11-03 | -$175.00K 10-Q · filed 2023-11-03 | -$506.00K derived: sum of 4 quarters · filed 2023-11-03 |
| 2023-06-30 | $692.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $891.00K 10-Q · filed 2023-08-03 | $560.00K derived: sum of 3 quarters · filed 2023-08-03 | $512.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $199.00K 10-Q · filed 2023-05-08 | -$132.00K derived: sum of 2 quarters · filed 2023-05-08 | -$180.00K derived: sum of 3 quarters · filed 2023-05-08 | -$1.24M derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | -$331.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$379.00K derived: sum of 2 quarters · filed 2023-02-28 | -$1.44M derived: sum of 3 quarters · filed 2023-02-28 | -$1.39M 10-K · filed 2023-02-28 |
| 2022-09-30 | -$48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.11M derived: sum of 2 quarters · filed 2022-11-03 | -$1.05M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.01M 10-Q · filed 2022-08-09 | ||
| 2022-03-31 | $51.00K 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |